Levomilnacipran is a member of acetamides.
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake. Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran]. Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.
Levomilnacipran is a Serotonin and Norepinephrine Reuptake Inhibitor. The mechanism of action of levomilnacipran is as a Norepinephrine Uptake Inhibitor, and Serotonin Uptake Inhibitor.
LEVOMILNACIPRAN is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for major depressive disorder and fibromyalgia and has 3 investigational indications. This drug has a black box warning from the FDA.
The (1S,2R)-isomer of milnacipran that is used for the treatment of MAJOR DEPRESSIVE DISORDER.
See also: Milnacipran (broader); Milnacipran Hydrochloride (related); Levomilnacipran Hydrochloride (active moiety of).

Levomilnacipran is derived from the chemical structure of milnacipran, which is synthesized through various chemical pathways. It is categorized under adrenergic uptake inhibitors and is recognized for its therapeutic effects in managing depression and anxiety disorders  .

The synthesis of levomilnacipran has been explored through several methodologies, with a focus on enantioselective approaches that yield the (1S,2R)-enantiomer. A notable method involves the use of phenylacetic acid as a starting material, where a highly enantioselective catalytic process is employed to construct the desired stereogenic centers.

Key Synthesis Steps

1. Starting Material: Phenylacetic acid serves as the precursor.
2. Catalytic Reaction: The reaction employs chiral catalysts to achieve high enantioselectivity.
3. Intermediate Formation: An enantioenriched lactone intermediate is formed, which is crucial for further transformations leading to levomilnacipran.
4. Final Product Isolation: The final product is isolated through crystallization or chromatography methods to ensure purity   .

Levomilnacipran has a complex molecular structure characterized by multiple functional groups that contribute to its pharmacological activity. Its molecular formula is C1717​H2222​N22​O, and it features a cyclopropane ring, which is integral to its mechanism of action.

Structural Features

• Molecular Weight: Approximately 274.37 g/mol.
• Chiral Centers: Two chiral centers at positions 1 and 2, contributing to its enantiomeric specificity.
• Functional Groups: Contains an amine group and a carbonyl group, which are essential for its interaction with neurotransmitter transporters  .

Levomilnacipran participates in various chemical reactions primarily related to its pharmacological activity. Its mechanism involves inhibition of serotonin and norepinephrine transporters, leading to increased levels of these neurotransmitters in the synaptic cleft.

Relevant Chemical Reactions

1. Reuptake Inhibition: Levomilnacipran binds to serotonin and norepinephrine transporters, blocking their reuptake.
2. Metabolic Pathways: It undergoes metabolic transformations primarily in the liver, where it is converted into various metabolites that may also exhibit pharmacological activity  .
3. Stability Reactions: Formulations often include stabilizing agents to enhance bioavailability and shelf-life .

Levomilnacipran’s mechanism of action involves dual inhibition of serotonin and norepinephrine reuptake transporters, with a stronger affinity for norepinephrine. This selective inhibition increases the extracellular concentrations of these neurotransmitters, thereby enhancing mood and alleviating depressive symptoms.

Mechanistic Insights

• Norepinephrine Reuptake Inhibition: Levomilnacipran shows a higher potency for norepinephrine reuptake inhibition compared to serotonin.
• Serotonin Reuptake Inhibition: While it also inhibits serotonin reuptake, this effect is less pronounced than its action on norepinephrine  .
• Therapeutic Effects: Increased levels of norepinephrine are associated with improved mood regulation and cognitive function in patients suffering from depression.

Levomilnacipran exhibits several physical and chemical properties that are relevant for its formulation and therapeutic use.

Key Properties

• Appearance: Typically appears as a white crystalline powder.
• Solubility: Soluble in water and organic solvents such as ethanol.
• Stability: Stable under normal conditions but sensitive to light and moisture; formulations often require specific excipients for stability  .
• Melting Point: The melting point range provides insights into its thermal stability during processing.

Levomilnacipran is primarily utilized in clinical settings for the treatment of major depressive disorder. Its unique profile allows it to be effective in patients who may not respond adequately to other antidepressants.

Scientific Applications

• Clinical Use: Approved for treating major depressive disorder in adults.
• Research Applications: Investigated for potential use in anxiety disorders due to its serotonergic and noradrenergic effects.
• Pharmaceutical Development: Ongoing research focuses on optimizing formulations and delivery systems to enhance patient outcomes  .

Dual Serotonin-Norepinephrine Reuptake Inhibition Dynamics

Levomilnacipran (LVM) is a potent dual serotonin-norepinephrine reuptake inhibitor (SNRI) distinguished by its preferential affinity for the norepinephrine transporter (NET) over the serotonin transporter (SERT). This selectivity profile differentiates it from other SNRIs and underpins its unique pharmacological activity.

Relative Potency Ratios (NE:5-HT) in Synaptic Transporter Binding

LVM exhibits a 2:1 potency ratio for NET versus SERT inhibition, as quantified through in vitro assays using human recombinant transporters. Key binding affinity values include:

• NET inhibition: K_i = 92.2 nM [8]
• SERT inhibition: K_i = 11.2 nM [8]

Despite the lower K_i value indicating higher SERT affinity, functional reuptake inhibition assays reveal greater potency for NET. Half-maximal inhibitory concentrations (IC₅₀) are:

• NET IC₅₀ = 10.5 nM
• SERT IC₅₀ = 19.0 nMThis yields a NET/SERT potency ratio of 0.6 (or 1:2 when expressed as NE:5-HT selectivity) [3] [8].

Table 1: Comparative Transporter Affinity and Potency of SNRIs [4] [8]

Compound	NET Ki (nM)	SERT Ki (nM)	NE:5-HT Potency Ratio
Levomilnacipran	92.2	11.2	1:2
Milnacipran	200	123	1:1.6
Duloxetine	8.9	0.2	1:10
Venlafaxine	>10,000	17.9	1:30

Dose-Dependent Modulation of Monoaminergic Selectivity

LVM’s monoaminergic effects are dose-dependent. At lower doses (e.g., 10 mg/kg in rodents), it preferentially increases extracellular norepinephrine (NE) levels in the prefrontal cortex. At higher doses (≥20 mg/kg), it achieves balanced NE and serotonin (5-HT) reuptake inhibition:

• ≥90% NET occupancy at doses ≥40 mg/day [7]
• ≥80% SERT occupancy at doses ≥40 mg/day [7]

This contrasts with other SNRIs (e.g., venlafaxine), which require doses >150 mg to significantly inhibit NET [2] [8].

Table 2: Dose-Dependent Reuptake Inhibition Profile of Levomilnacipran [2] [7] [8]

Daily Dose (mg)	NET Inhibition (%)	SERT Inhibition (%)	Dominant Activity
20	~70%	~50%	Noradrenergic
40–80	≥90%	70–80%	Balanced
≥120	>95%	>85%	Balanced (slight NE bias)

Receptor Binding Profiles and Off-Target Affinities

Lack of Muscarinic, Histaminergic, or Adrenergic Receptor Interactions

A defining feature of LVM is its high target specificity. Screening against 23 neurotransmitter receptors, ion channels, and transporters confirmed:

• No significant affinity for muscarinic acetylcholine receptors (IC₅₀ > 100,000 nM) [1] [3]
• Negligible binding to histamine H₁ receptors (IC₅₀ > 100,000 nM) [1]
• Minimal interaction with α₁-, α₂-, or β-adrenergic receptors (IC₅₀ > 10,000 nM) [3] [8]

This clean off-target profile reduces side effects associated with non-selective antidepressants (e.g., sedation, orthostatic hypotension) [1].

NMDA Receptor Antagonism at Supra-Clinical Concentrations

At supra-therapeutic concentrations (>1 µM), LVM acts as an NMDA receptor antagonist. Key findings include:

• Binds the dizocilpine (MK-801) site on NMDA receptors (K_i = 1.7 µM) [5]
• Inhibits NR2A subunit-containing NMDA receptors (IC₅₀ = 5.62 µM) [8]
• Inhibits NR2B subunit-containing NMDA receptors (IC₅₀ = 4.57 µM) [8]

This activity occurs at concentrations 10–50 times higher than therapeutic plasma levels (C_max ≈ 341 ng/mL or 1.38 µM at 120 mg/day) [1] [6]. While irrelevant for antidepressant effects, it may contribute to neuroprotective effects in non-clinical models [5].

Table 3: NMDA Receptor Inhibition by Levomilnacipran [5] [8]

NMDA Receptor Subtype	IC50 (µM)	Clinical Relevance
NR2A	5.62	Supra-therapeutic (>3× Cmax at 120 mg)
NR2B	4.57	Supra-therapeutic (>3× Cmax at 120 mg)
MK-801 binding site	Ki = 1.7	Supra-therapeutic (>1× Cmax at 120 mg)